<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IFOSFAMIDE</span><br/>(i-fos'-fa-mide)<br/><span class="topboxtradename">Ifex<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 g, 3 g vials</p>
<h1><a name="action">Actions</a></h1>
<p>Ifosfamide is a chemotherapeutic agent chemically related to nitrogen mustards. The alkylated metabolites of ifosfamide interact
         with DNA.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antineoplastic or cytotoxic action is primarily due to cross-linking of strands of DNA and RNA as well as inhibition of protein
         synthesis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other agents in various regimens for germ cell testicular cancer, soft tissue sarcomas, Ewing's sarcoma,
         and non-Hodgkin's lymphoma. Also for lung and pancreatic sarcoma.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with severe bone marrow depression or who have demonstrated previous hypersensitivity to ifosfamide; pregnancy (category
         D) and lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal function, prior radiation or prior therapy with other cytotoxic agents.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antineoplastic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.2 g/m<sup>2</sup>/d for 5 consecutive d; administer over at least 30 min, repeat q3wk or after recovery from hematologic toxicity (platelets
               <img src="../images/special/greaterorequal.gif"/>100,000/mm<sup>3</sup>; WBC <img src="../images/special/greaterorequal.gif"/>4,000/mm<sup>3</sup>)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Dilute each 1 g in 20 mL of sterile water or bacteriostatic water to yield 50 mg/mL. Shake well to dissolve. May be further diluted with D5W, NS, or RL to achieve concentrations of 0.620 mg/mL. Use solution prepared with sterile water within 6 h. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give slowly over 30 min.  
               </p>
<ul>
<li>
                     						Note: Mesna is always given concurrently with ifosfamide; never give ifosfamide alone.
                     					
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution prepared with bacteriostatic solution up to a week at 30° C (86° F) or 6 wk at 5°
            C (41° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Somnolence, confusion, hallucinations,</span> coma, dizziness, seizures, cranial nerve dysfunction. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> anorexia, diarrhea, metabolic acidosis, hepatic dysfunction. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Neutropenia, thrombocytopenia</span>. <span class="typehead">Urogenital:</span>
<span class="speceff-life">Hemorrhagic cystitis, nephrotoxicity</span>. <span class="typehead">Skin:</span>
<span class="speceff-common">Alopecia,</span> skin necrosis with extravasation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">hepatic enzyme inducers (barbiturates</span>, <b>phenytoin,</b>
<b>chloral hydrate</b>) may increase hepatic conversion of ifosfamide to active metabolite; <span class="classification">corticosteroids</span> may inhibit conversion to active metabolites. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active form. <span class="typehead">Elimination:</span> 7086% excreted in urine. <span class="typehead">Half-Life:</span> 715 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC with differential prior to each dose and at regular intervals; urinalysis prior to each dose for microscopic
            hematuria.
         </li>
<li>Hold drug and notify physician if WBC count is below 2000/mm<sup>3</sup> or platelet count is below 50,000/mm<sup>3</sup>.
         </li>
<li>Reduce risk of hemorrhagic cystitis by hydrating with 3000 mL of fluid daily prior to therapy and for at least 72 h following
            treatment to ensure ample urine output.
         </li>
<li>Discontinue therapy if any of the following CNS symptoms occur: Somnolence, confusion, depressive psychosis, and hallucinations.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Void frequently to lessen contact of irritating chemical with bladder mucosa.</li>
<li>
            							Note: Susceptibility to infection may increase. Avoid people with infection. Notify physician of any infection, fever or chills,
            cough or hoarseness, lower back or side pain, painful or difficult urination.
            						
         </li>
<li>Check with physician immediately if there is any unusual bleeding or bruising, black tarry stools, or blood in urine or if
            pinpoint red spots develop on skin.
         </li>
<li>Discuss possible adverse effects (e.g., alopecia, nausea, and vomiting) and measures that can minimize them with health care
            provider.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>